pralsetinib

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Sun, 09/6/20 - 07:22 pm
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib
Pharmaceutical Business Review
Tue, 07/14/20 - 10:29 am
Roche
Blueprint Medicines
pralsetinib
RET-altered cancer